WASHINGTON, D.C. — The National Institutes of Health announced a December‑launch initiative to accelerate development of therapeutic cancer vaccines, mirroring the rapid pathway used for Covid‑19 shots, officials said on Tuesday.

The program, dubbed “Vax‑Onc,” will funnel $250 million into three vaccine candidates that have completed Phase 2 trials. In those studies, the leading candidate cut tumor recurrence by 48 % in patients with melanoma, while showing a safety profile comparable to existing immunotherapies, according to a briefing document released by the NIH.

KEY POINTThe program, dubbed “Vax‑Onc,” will funnel $250 million into three vaccine candidates that have completed Phase 2 trials.

“We are applying the lessons learned from the pandemic to oncology,” said Dr. Emily Chen, director of the National Cancer Institute’s Immunotherapy Division. “Fast‑track designation from the FDA, combined with coordinated manufacturing support, could shave years off the time it takes to bring a vaccine from the lab to the clinic.” The FDA has granted Breakthrough Therapy designation to all three candidates, a status that expedites review and allows for rolling submissions of data.

Patient advocacy groups welcomed the move but cautioned that real‑world impact will depend on equitable distribution. “My sister’s trial showed promise, but access remains a hurdle for many communities,” said Maria Lopez, founder of the Cancer Vaccine Alliance. The initiative includes a commitment to enroll at least 1,200 diverse participants across 15 trial sites, aiming to address the historic under‑representation of minority patients in oncology studies.

Clinicians anticipate that an effective vaccine could complement checkpoint inhibitors, potentially reducing reliance on high‑dose chemotherapy. A recent meta‑analysis published in *Lancet Oncology* found that adding a vaccine to standard therapy lowered overall mortality by 12 % in solid‑tumor trials, a statistic the NIH hopes to improve upon with its accelerated pipeline.

Should the vaccines meet efficacy thresholds, the NIH plans to submit a Biologics License Application to the FDA by mid‑2025, with a target commercial launch in early 2026. The timeline reflects a coordinated effort among federal agencies, private manufacturers, and academic centers to replicate the speed that delivered Covid‑19 vaccines in under a year.

Key Takeaways

• NIH allocates $250 million to fast‑track three cancer vaccine candidates, each with FDA Breakthrough Therapy designation.
• Phase 2 data show up to 48 % reduction in tumor recurrence and safety comparable to existing immunotherapies.
• Goal to enroll 1,200 diverse patients and submit FDA licensing applications by mid‑2025.

The accelerated pathway underscores a strategic shift toward preventive oncology, aiming to deliver therapies that not only treat but also pre‑empt disease progression for millions of patients.